Pfizer Reports Q3 2026 Earnings Beat and Raises Full-Year Guidance
Pfizer (PFE) reported third-quarter 2026 revenue of $16.58 billion and adjusted earnings per share (EPS) of $0.87, surpassing market consensus. The company's non-COVID portfolio demonstrated strength with a 7% operational growth rate, while launched and acquired products saw a significant 32% increase, helping to mitigate the impact of declining COVID-related sales. Following these results, management raised its full-year 2026 guidance for the second time this year. The company now projects annual revenue between $62 billion and $64 billion, with adjusted EPS expected in the range of $2.95 to $3.05. With a dividend yield of 5.73% well-supported by free cash flow, analysts suggest that current market pessimism regarding long-term deceleration may be overstated.
Tickers: $PFE
Topics: dividend yield earnings report guidance raise revenue growth